期刊文献+

108例儿童肺炎支原体肺炎的临床特点及并发症分析 被引量:18

下载PDF
导出
摘要 目的分析儿童肺炎支原体(mycoplasma pneumoniae,MP)肺炎临床及并发症特点,进一步明确该病的诊断和治疗。方法回顾性分析108例儿童肺炎支原体肺炎临床病例资料。结果发病年龄多为学龄和学龄前儿童,6~14岁占44.4%,3~6岁占33.3%;持续发热伴刺激性咳嗽的患儿占95.4%,部分年长儿可伴胸痛,婴幼儿可伴喘憋;胸片均有明显改变,但无特异性;40.7%有肺外并发症表现,以肝损害、肾炎、心肌缺血、皮肤黏膜损害多见;MP痰培养阳性率偏低(28.2%),血清MP-IgM检测均为阳性;所有病例用大环内酯类药物如阿奇霉素治疗效果良好,尚未发现耐药情况。结论MP肺炎主要为学龄和学龄前儿童发病,并且好发年龄有提前趋势,临床和胸片表现与其他病原体引起的肺炎无显著差异,肺外表现为多系统、多器官损害,血清MP-IgM检测可用于确诊和早期诊断,大环内酯类药物治疗效果好。
作者 闫军 叶海燕
出处 《重庆医学》 CAS CSCD 2008年第11期1224-1226,共3页 Chongqing medicine
  • 相关文献

参考文献10

  • 1Nagalingam NA, Adesiyon AA, Swanaton WH, at al. Prevalence of mycoplasma pneumoniae and chlamydia pneumoniae in pneumonia patients in four major hospital in Trinidad[J]. New Microbiol, 2004,27 (4) : 345.
  • 2胡亚美 江载芳.诸福棠实用儿科学[M]第7版[M].北京:人民卫生出版社,2002.1514.
  • 3MargaretR.Hammerschlag,周宝桐,盛瑞媛.肺炎支原体感染[J].世界医学杂志,2003,7(3):22-26. 被引量:2
  • 4Principi N, Esposito S. Mycoplasma pneumoniae and chlamydia pneumoniae cause lower respiratory tract diease in paediatric patients[J]. Curr Opin Infect Dis, 2002,15:295.
  • 5Sutherland ER,Brandirff JM, Martin RJ. A typical bacterial pneumonia and asthma rsthma risk[J]. J Asthma,2004,41(8):863.
  • 6张晗,尚云晓.支原体感染与支气管哮喘[J].国外医学(儿科学分册),2003,30(5):236-239. 被引量:141
  • 7徐慧香,张慧燕,车大钿,陆敏.小儿肺炎支原体肺炎106例临床分析[J].中国实用儿科杂志,2007,22(1):51-52. 被引量:142
  • 8Said MH, Layani MP. Mycoplasma pneumoniae-associated nephritis in children[J].Pediatr Nephrol, 1999, 13 (1) : 39.
  • 9肖纫霞,宋丽君,王朝霞,郭亚珍.肺炎支原体抗体IgM阳性川崎病3例报告[J].中国实用儿科杂志,2002,17(7):437-437. 被引量:12
  • 10Candler PM,Dale RC. Three cases of center nervous system complications associated with Mycoplasma pneumoniae [J]. Pediatr Neurol, 2004,31 (2) : 133.

二级参考文献43

  • 1胡亚美 江载芳.诸福棠实用儿科学[M] 7版[M].北京:人民卫生出版社,2002.698-705.
  • 2Hardegger D, Nadal D, Bossart W, et al. Rapid detection of Mycoplasma pneumoniae in clinical samples by realtime PCR. J Microbiol Methods 2000; 42:45-51.
  • 3Taylor-Robinson D, Bebear C. Antibiotic susceptibilities of mycoplasmas and treatment of mycoplasmal infections. J Antimicrob Chemother 1997; 40: 622-630.
  • 4Yamaguchi T, Hiraakata Y, Izumikawa K, et al. In vitro activity oftelithromycin(HMR3647), a new ketolide, against clinical isolates of Mycoplasma pneumoniae in Japan. Antimicrob Agents Chemother 2000; 44: 1381-1382.
  • 5Hannan PCT, Woodnutt G. In vitro activity of gemifloxacin (SB 265805;LB2200003304a) against human mycoplasmas. J Antimicrob Chemother 2000;45: 367-369.
  • 6Duffy LB, Crabb D, Searcey K, Kempf MC. Comparative potency of gemifloxiacin,new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp. J Antimicrob Chemother 2000; 45 (Suppl. 1): S529-S533.
  • 7Rasch JR, Mogabgab WJ. Therapeutic effect of erythromycin on Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother 1965; 5: 693-699.
  • 8Shames JM, George RB, Holliday WB, et al. Comparison Of antibiotics in the treatment ofmycoplasmal pneumonia. Arch Intern Med 1970; 125: 680-684.
  • 9Smith CB, Friedwell WT, Chanock RM. Shedding of Mycoplasma pneumoniae after tetracycline and erythromycin. N Engl J Med 1967, 276:1172-1175.
  • 10Anderson G, Esmond TS, Coles S, et al. A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community acquired pneumonia. J Antimicrob Chemother 1991; 27 (Suppl. A): 117-124.

共引文献1481

同被引文献158

引证文献18

二级引证文献121

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部